BIOA BioAge Labs, Inc.
Price Chart
Executive Summary
BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor) for cardiovascular risk reduction. Topline data expected H2 2026 — a routine operational milestone with no financial or efficacy data disclosed.
Actionable Insight
No immediate stock-moving catalyst; traders should monitor for topline Phase 2 data in H2 2026. Phase 1 hsCRP reductions were strong, but Phase 2 proof-of-concept is still highly binary and carries clinical risk. Given poor historical calibration on BIOA (T+20 avg -12.9%, 13% win rate), conservative positioning is warranted until actual data readout.
Key Facts
- First participant dosed in Phase 2 trial QUELL-CV evaluating BGE-102
- Trial is randomized, double-blind, placebo-controlled, dose-ranging (30/60/90 mg QD) in ~160 participants
- Primary endpoint: percent change from baseline in hsCRP
- Topline data anticipated in second half of 2026
- Phase 1 data previously showed 86% median hsCRP reduction at 60 mg and 120 mg doses
Financial Impact
No financial data in release; $882M market cap, clinical-stage company with no revenue
Risk Factors
- Phase 2 may fail to replicate Phase 1 hsCRP reductions or show clinical benefit
- Competition from other NLRP3 inhibitors and anti-inflammatory cardiovascular therapies
- No approved products or revenue; capital needs for further development
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312476 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 16, 2026
4d ago
|
Press Release
| $20.49 $19.99 | ▼ −2.44% | ▼ −1.19% | $20.77 (+1.37%) |
|
May 8, 2026
6w ago
|
8-K
| $17.99 $18.16 | ▲ +0.94% | ▲ +0.71% | $20.77 (+15.45%) |
|
Apr 21, 2026
8w ago
|
DEFA14A
| $18.36 $17.24 | ▼ −6.10% | ▼ −5.71% | $20.77 (+13.13%) |
|
Apr 21, 2026
8w ago
|
Press Release
| $19.61 $18.36 | ▼ −6.37% | ▼ −7.39% | $20.77 (+5.92%) |
|
Apr 1, 2026
11w ago
|
144
| $17.73 $17.50 | ▼ −1.30% | ▼ −1.38% | $20.77 (+17.15%) |
|
Mar 24, 2026
12w ago
|
Press Release
| $16.11 $16.41 | ▲ +1.86% | ▲ +1.30% | $20.77 (+28.93%) |
|
Feb 28, 2026
16w ago
|
Institutional Cluster
| $21.71 $20.46 | ▼ −5.76% | ▼ −4.84% | $20.77 (−4.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access